ID: ALA101299

Max Phase: Preclinical

Molecular Formula: C20H16FN3O4

Molecular Weight: 381.36

Molecule Type: Small molecule

Associated Items:

Representations

Synonyms (1): A-62176
Synonyms from Alternative Forms(1):

    Canonical SMILES:  N[C@H]1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2Oc2ccccc2-4)C1

    Standard InChI:  InChI=1S/C20H16FN3O4/c21-13-7-11-16-19(17(13)23-6-5-10(22)8-23)28-15-4-2-1-3-14(15)24(16)9-12(18(11)25)20(26)27/h1-4,7,9-10H,5-6,8,22H2,(H,26,27)/t10-/m0/s1

    Standard InChI Key:  OLNJLTFSGFZCKE-JTQLQIEISA-N

    Associated Targets(Human)

    DNA topoisomerase II 1334 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    MDA-MB-231 73002 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    NCI-H226 44470 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    HT-29 80576 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Raji 5516 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    DU-145 51482 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    HeLa 62764 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    MCF7 126967 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    NCI-H520 551 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    RPMI-8226 44974 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    U-937 7138 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Granta 22 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    MIA PaCa-2 5949 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Associated Targets(non-human)

    B16 5829 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Molecule Features

    Natural Product: NoOral: NoChemical Probe: NoParenteral: No
    Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
    Chirality: NoAvailability: NoProdrug: No

    Drug Indications

    MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Properties

    Molecular Weight: 381.36Molecular Weight (Monoisotopic): 381.1125AlogP: 2.47#Rotatable Bonds: 2
    Polar Surface Area: 97.79Molecular Species: ZWITTERIONHBA: 6HBD: 2
    #RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
    CX Acidic pKa: 5.24CX Basic pKa: 9.63CX LogP: -0.26CX LogD: -0.26
    Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.55Np Likeness Score: -0.36

    References

    1. Kim MY, Na Y, Vankayalapati H, Gleason-Guzman M, Hurley LH..  (2003)  Design, synthesis, and evaluation of psorospermin/quinobenzoxazine hybrids as structurally novel antitumor agents.,  46  (14): [PMID:12825936] [10.1021/jm030096i]
    2. Zeng Q, Kwok Y, Kerwin SM, Mangold G, Hurley LH..  (1998)  Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.,  41  (22): [PMID:9784102] [10.1021/jm980265c]
    3. Kim MY, Duan W, Gleason-Guzman M, Hurley LH..  (2003)  Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.,  46  (4): [PMID:12570378] [10.1021/jm0203377]
    4. Xu H, Hurley LH..  (2022)  A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex).,  77  [PMID:36195286] [10.1016/j.bmcl.2022.129016]

    Source